Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Alesini

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
The Lancet. Oncology|March 8, 2016
Palbociclib: efficacious but predictive biomarkers still neededFrancesco Cognetti, Paola Malaguti, Daniele Alesini
Anti-Cancer Agents in Medicinal Chemistry|November 13, 2012
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancerAntonio Passaro, Daniele Alesini, Alessia Pochesci, et al.
Therapeutic Advances in Urology|October 2, 2015
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaDaniele Alesini, Claudia Mosillo, Giuseppe Naso, et al.
Urology|June 27, 2013
Clinical and pathological features of primary neuroectodermal tumor/Ewing sarcoma of the kidneyEmanuela Risi, Roberto Iacovelli, Amelia Altavilla, et al.
Cancer Biology & Therapy|July 25, 2012
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantAmelia Altavilla, Roberto Iacovelli, Giuseppe Procopio, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2013
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?Antonio Passaro, Morena Fasano, Emilio Bria, et al.
Cancer Treatment Reviews|September 28, 2013
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trialsRoberto Iacovelli, Daniele Alesini, Antonella Palazzo, et al.
Oncology|November 7, 2012
Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen moleculesDaniele Alesini, Roberto Iacovelli, Antonella Palazzo, et al.
Investigational New Drugs|February 19, 2013
Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective studyLuca Moscetti, Fabrizio Nelli, Maria A Fabbri, et al.
Frontiers in Oncology|February 28, 2022
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the LiteratureAndrea Botticelli, Agnese Fabbri, Michela Roberto, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
The Lancet. Oncology|March 8, 2016
Palbociclib: efficacious but predictive biomarkers still neededFrancesco Cognetti, Paola Malaguti, Daniele Alesini
Anti-Cancer Agents in Medicinal Chemistry|November 13, 2012
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancerAntonio Passaro, Daniele Alesini, Alessia Pochesci, et al.
Therapeutic Advances in Urology|October 2, 2015
Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaDaniele Alesini, Claudia Mosillo, Giuseppe Naso, et al.
Urology|June 27, 2013
Clinical and pathological features of primary neuroectodermal tumor/Ewing sarcoma of the kidneyEmanuela Risi, Roberto Iacovelli, Amelia Altavilla, et al.
Cancer Biology & Therapy|July 25, 2012
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistantAmelia Altavilla, Roberto Iacovelli, Giuseppe Procopio, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2013
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?Antonio Passaro, Morena Fasano, Emilio Bria, et al.
Cancer Treatment Reviews|September 28, 2013
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trialsRoberto Iacovelli, Daniele Alesini, Antonella Palazzo, et al.
Oncology|November 7, 2012
Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen moleculesDaniele Alesini, Roberto Iacovelli, Antonella Palazzo, et al.
Investigational New Drugs|February 19, 2013
Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective studyLuca Moscetti, Fabrizio Nelli, Maria A Fabbri, et al.
Frontiers in Oncology|February 28, 2022
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the LiteratureAndrea Botticelli, Agnese Fabbri, Michela Roberto, et al.
Pageof 3